Saturday 17 October 2026
Export ARTL’s income statement to Excel — free account
Artelo Biosciences, Inc.
ARTL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.7% and free cash flow fell 879.2%, each against the same quarter a year earlier.
2.70
0.04
−1.46%
Follow ARTL
Artelo Biosciences, Inc. (ARTL) P/E ratio
Artelo Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEXI NexImmune, Inc. compare | n/m |
| ARTL Artelo Biosciences, Inc. | n/m |
| CARM Carisma Therapeutics Inc. compare | n/m |
| MLEC Moolec Science SA compare | n/m |
| TRVN Trevena, Inc. compare | n/m |
| ITRMF Iterum Therapeutics PLC compare | n/m |
| GNPX GENPREX compare | 0.0× |
| ABPO Abpro Holdings Inc. compare | 0.2× |
| PTIX Atrinsic Inc. compare | 0.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)